Companion Animal Diagnostics Market Size, Revenue, CAGR Analysis & Forecast, 2026-2035
The global companion animal diagnostics market is valued at USD 6.24 billion in 2025 and is projected to reach USD 15.61 billion by 2035, advancing at a 9.6% CAGR from 2026–2035. Within this expanding market, the strongest structural shift is toward technologies that can deliver more specific and actionable clinical information.
Molecular diagnostics is emerging as a particularly important technology because veterinary providers are increasingly looking beyond broad clinical indicators toward precise identification of infectious diseases and complex conditions. This creates value not simply through better detection, but through the ability to support more targeted treatment decisions.
The shift also reflects changing expectations around companion animal healthcare. As pet owners become more willing to invest in advanced veterinary services, diagnostic testing is moving from a reactive tool used after symptoms appear toward a more integrated component of disease management.
Point-of-care molecular platforms are especially significant because they can shorten the distance between testing and clinical decision-making. Faster access to diagnostic information can improve workflow efficiency for veterinary practices while making advanced testing more practical outside large reference laboratories.
For diagnostic companies, the opportunity therefore extends beyond selling individual tests. Providers that combine molecular testing with accessible workflows, automated processing, and broader diagnostic portfolios could be better positioned to capture the market's movement toward precision-oriented veterinary care.
Regional Analysis: North America's Scale Meets Asia Pacific's Growth Momentum
North America currently holds the strongest position in the companion animal diagnostics market, accounting for 40.18% of the market. Asia Pacific, meanwhile, represents the fastest-growing regional opportunity, supported by a 10.85% CAGR.
The difference between the two regions illustrates two distinct stages of market development.
North America: Established Diagnostic Intensity
North America's leadership is closely associated with mature veterinary infrastructure, high levels of pet healthcare spending, and established integration between veterinary clinics and reference laboratories. Diagnostic testing is already embedded into routine clinical workflows, giving providers a relatively sophisticated foundation for adopting new technologies.
This makes the region particularly attractive for advanced diagnostic solutions, including molecular platforms, automated testing, and AI-enabled imaging. The commercial opportunity is less about introducing diagnostics to the market and more about upgrading existing diagnostic practices and expanding testing intensity.
Asia Pacific: Expansion Through Capacity Building
Asia Pacific presents a different opportunity. Rising pet ownership, expanding veterinary clinic networks, and increasing demand for early disease detection are creating the conditions for rapid diagnostic adoption.
The region's growth potential is particularly relevant for companies seeking markets where veterinary infrastructure is still developing. Investments in laboratory capacity, point-of-care systems, practitioner education, and accessible testing formats could help establish long-term demand.
The strategic implication is clear: North America offers depth, while Asia Pacific offers expansion velocity. Companies with established portfolios may prioritize North America for premium and advanced diagnostics while using Asia Pacific to build new customer bases and extend diagnostic penetration.
Industry Challenge: Advanced Diagnostics Must Overcome Adoption and Access Barriers
The growth of companion animal diagnostics does not automatically translate into uniform adoption of advanced testing. One of the industry's central challenges is balancing technological sophistication with the practical requirements of veterinary practices.
Highly advanced diagnostic platforms can deliver more precise information, but their value depends on whether veterinary providers can incorporate them efficiently into everyday workflows. Smaller or less technologically equipped practices may face limitations related to infrastructure, technical expertise, testing workflows, and access to specialized laboratory services.
This creates an important distinction between diagnostic capability and diagnostic usability.
The industry's expansion of point-of-care and in-house testing suggests that accessibility is becoming an increasingly important competitive factor. Technologies that allow practitioners to obtain useful diagnostic information closer to the time of consultation can reduce dependence on external testing pathways and support faster clinical decisions.
Another challenge is ensuring that increased testing translates into meaningful clinical value. As diagnostic menus become broader, veterinary professionals need solutions that provide interpretable results rather than simply generating more data.
This places pressure on diagnostic companies to compete on workflow integration, automation, ease of use, and clinical relevance—not only analytical performance.
The commercial winners may therefore be companies capable of making sophisticated diagnostics operationally simple. The ability to fit advanced technology into routine veterinary practice could prove just as important as the underlying diagnostic technology itself.
Segment Comparison: Clinical Biochemistry vs. Molecular Diagnostics
Clinical biochemistry and molecular diagnostics represent two different but complementary approaches to companion animal testing.
|
Dimension |
Clinical Biochemistry |
Molecular Diagnostics |
|
Primary role |
Routine health assessment and organ function evaluation |
High-specificity identification of infectious and complex conditions |
|
Market position |
Established, high-use diagnostic segment |
Fastest-growing technology segment |
|
Typical value |
Supports routine monitoring and chronic-condition management |
Supports more precise disease identification |
|
Adoption driver |
Integration into everyday veterinary practice |
Demand for specificity and precision |
|
Opportunity |
Continued routine diagnostic utilization |
Expansion of advanced and targeted testing |
Clinical biochemistry captured 24.79% of the market in 2025, reflecting its established role in health assessments, organ function evaluation, and management of common chronic conditions.
Its strength comes from routine applicability. Veterinary practices can use biochemical testing across a broad range of clinical situations, making it an important foundation of everyday diagnostic care.
Molecular diagnostics operates differently. Rather than competing directly with routine biochemical testing, it expands the diagnostic toolkit by addressing situations where higher specificity is required.
This distinction creates opportunities for both segments. Clinical biochemistry benefits from its broad and established clinical utility, while molecular diagnostics has greater room to gain adoption as veterinary providers seek more precise diagnostic answers.
The longer-term market opportunity may therefore lie in portfolio integration rather than substitution. Diagnostic providers capable of offering routine testing alongside advanced molecular capabilities can address a wider range of clinical requirements and strengthen their position across the veterinary workflow.
Geographic Opportunity: Four Markets With Strategic Relevance
Several national markets stand out because of their relationship with established diagnostic companies, veterinary infrastructure, or regional expansion opportunities.
United States
The United States represents a strategically important market because several major participants—including IDEXX Laboratories, Zoetis, Thermo Fisher Scientific, Antech Diagnostics, Neogen, and Embark Veterinary—are based there.
Its importance extends beyond domestic demand. The concentration of established diagnostic businesses creates an ecosystem of laboratory capabilities, technology development, veterinary networks, and commercial expertise that can influence innovation across the broader market.
Japan
Japan provides an important Asian market presence through Fujifilm Corporation. Its strategic relevance is strengthened by the broader growth opportunity emerging across Asia Pacific.
For diagnostic companies, Japan can serve as an important market for advanced technology adoption while also providing a pathway into a region where veterinary infrastructure and demand for companion animal healthcare are expanding.
France
France is represented by established participants including Virbac and bioMérieux. This provides the country with strategic importance within the European veterinary and diagnostics ecosystem.
The presence of companies spanning animal health and diagnostic expertise can support technology development and commercial expansion across European markets.
United Kingdom and Ireland
The UK and Ireland gained additional strategic significance following Zoetis' acquisition of Veterinary Pathology Group in November 2025. The transaction gave Zoetis its first owned reference laboratories in the region and strengthened its ability to integrate point-of-care and reference laboratory capabilities.
This makes the market particularly relevant from a laboratory-network perspective. The development illustrates how geographic expansion can be pursued not only through product sales but also through ownership and integration of diagnostic infrastructure.
Competitive Landscape: Integration Is Becoming a Key Strategic Theme
Competition in companion animal diagnostics is increasingly extending beyond individual diagnostic products. Leading participants are positioning themselves across laboratory services, molecular technologies, pathology, imaging, automation, and specialized veterinary applications.
Key participants include IDEXX Laboratories Inc., Zoetis Inc., Thermo Fisher Scientific Inc., Antech Diagnostics Inc., Fujifilm Corporation, Virbac S.A., bioMérieux SA, Neogen Corporation, Embark Veterinary Inc., and Esaote S.p.A.
Recent strategic activity indicates three notable competitive directions.
First, diagnostic infrastructure is becoming strategically valuable. Zoetis' acquisition of Veterinary Pathology Group demonstrates how companies can strengthen their market position by controlling reference laboratory capabilities in addition to point-of-care solutions.
Second, intellectual property is becoming increasingly important in automated diagnostics. Zomedica's expansion of its patent portfolio around TRUVIEW digital cytology and TRUFORMA diagnostic platforms highlights the importance of protecting technologies involving automated slide processing and sensor capabilities.
Third, cross-sector partnerships are broadening diagnostic applications. Hill's Pet Nutrition's partnership with MiDOG Animal Diagnostics demonstrates how microbiome sequencing can connect diagnostics with nutrition research and personalized care.
Together, these developments suggest that competition is moving toward broader ecosystems. Companies are increasingly seeking combinations of diagnostic technology, laboratory infrastructure, intellectual property, data, and specialized clinical applications rather than relying on a single product category.
Recent Industry News: Strategic Moves Point Toward More Integrated Veterinary Diagnostics
Zoetis — November 2025
Zoetis acquired Veterinary Pathology Group (VPG), a diagnostic laboratory network operating across the UK and Ireland. The transaction gave Zoetis its first owned reference laboratories in the region and strengthened its ability to combine point-of-care solutions with sophisticated reference laboratory capabilities.
Industry implication: The move illustrates the growing strategic value of integrated diagnostic networks. Owning laboratory infrastructure can allow companies to connect different stages of the diagnostic journey and potentially create a more comprehensive veterinary service model.
Zomedica — September 2025
Zomedica expanded its intellectual property portfolio through the issuance of four U.S. patents covering its TRUVIEW digital cytology and TRUFORMA diagnostic platforms. The patents strengthen protection around automated slide processing and sensor technology.
Industry implication: Intellectual property is becoming an important competitive lever as veterinary diagnostics becomes increasingly automated. Protected technologies can help companies differentiate platforms and establish longer-term positions in specialized diagnostic categories.
Hill's Pet Nutrition — May 2025
Hill's Pet Nutrition formed a strategic partnership with MiDOG Animal Diagnostics to integrate advanced microbiome sequencing into veterinary care and nutrition research. The collaboration is intended to use high-precision microbial diagnostics to support targeted clinical approaches and personalized nutritional solutions.
Industry implication: The development points toward a broader convergence between diagnostics, nutrition, and preventive care. Rather than treating diagnostic testing as an isolated clinical service, industry participants are increasingly exploring how diagnostic information can guide more individualized health-management strategies.
Overall, the recent developments indicate that the companion animal diagnostics market is evolving toward integration, precision, automation, and personalized care. Laboratory ownership, protected diagnostic technologies, and specialized partnerships are becoming important mechanisms for capturing value as veterinary diagnostics moves beyond conventional testing toward a more connected healthcare model.
Read more about this report @
https://www.fundamentalbusinessinsights.com/industry-report/companion-animal-diagnostics-market-2449
About Fundamental Business Insights:
Fundamental Business Insights is global market research and consulting company which is engaged in providing in depth market reports to its various types of clients like industrial sectors, financial sectors, universities, non-profit, and corporations. Our goal is to offer the correct information to the right stakeholder at the right time, in a format that enables logical and informed decision making. We have a team of consultants who have experience in offering executive level blueprints of markets and solutions. Our services include syndicated market studies, customized research reports, and consultation.
Contact us:
Robbin Fernandez
Head of Business Development
Fundamental Business Insights and Consulting
Email: sales@fundamentalbusinessinsights.com
Read This Report in Regional Languages -
